3SBio Inc. (FRA:83B)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.03B +75.6% |
| Revenue (ttm) | 2.15B +94.3% |
| Net Income | 1.03B +305.8% |
| EPS | 0.42 +303.6% |
| Shares Out | n/a |
| PE Ratio | 5.84 |
| Forward PE | 16.67 |
| Dividend | 0.03 (1.05%) |
| Ex-Dividend Date | Jul 21, 2025 |
| Volume | 100 |
| Average Volume | n/a |
| Open | 2.391 |
| Previous Close | 2.602 |
| Day's Range | 2.345 - 2.391 |
| 52-Week Range | 1.250 - 3.880 |
| Beta | n/a |
| RSI | 42.60 |
| Earnings Date | Mar 30, 2026 |
About 3SBio
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex... [Read more]
Financial Performance
In 2025, 3SBio's revenue was 17.70 billion, an increase of 94.29% compared to the previous year's 9.11 billion. Earnings were 8.48 billion, an increase of 305.78%.
Financial numbers in CNY Financial StatementsNews
Mega Licensing Deal Boosts 3SBio Profits But Core Sales Slip
The Chinese drugmaker delivered sharply higher earnings, thanks to a bumper deal with Pfizer to develop a new cancer drug, but its older products came under pressure image credit: Bamboo Works Key Tak...